I n this issue of Circulation: Arrhythmia and Electrophysiology, Kim et al 1 evaluate the relationship between the international normalized ratio (INR) level on the day of radiofrequency catheter ablation for atrial fibrillation (AF) and the rate of periprocedural complications. With the expanding role of ablation in the treatment of AF, defining the optimal strategy for managing anticoagulation therapy in the periprocedural period is crucial to avoid both bleeding and thromboembolic complications. Prior studies have shown that uninterrupted therapeutic anticoagulation with warfarin may be the safest approach because it avoids significant fluctuations in anticoagulation. [2] [3] [4] [5] When warfarin is held before the procedure and then resumed, the use of unfractionated or low molecular weight heparin as bridging therapy becomes necessary. When warfarin is continued during the periprocedural period, bridging is unnecessary, but the optimal range of INR is not known. Kim et al 1 try to address this question in their retrospective study by examining categories of INR and the risk of vascular access complications, cardiac tamponade, bleeding, and thromboembolism in 1133 patients who underwent the AF ablation for >2-year period. Almost half of the patients had persistent AF; the average CHADS-2 score was ≈1. Although patients were asked to continue warfarin up to the day of the procedure, the INR was within the range of 2 to 3 in only 50% of the patients; 43% of the patients had a subtherapeutic level; and 7% had an INR >3. Bleeding occurred in 8% of the patients and included cardiac tamponade (1%) and vascular complications requiring intervention (2%). This data provide yet another indication of the risks associated with AF ablation, even when done at large centers and by experienced operators. Most of the bleeding was minor (groin hematomas), not requiring additional treatment, and one could argue that this is an acceptable level of risk. Analysis of the risk of complications based on the INR level showed that the relationship between these 2 variables follows a U-shaped curve. From a practical standpoint, an INR value falling <1.5 or >3.5 is associated with an unacceptably high rate of bleeding complications. This risk is likely because of the need for high doses of heparin in the former group, and the excessive anticoagulant effect of warfarin in the latter. This observation may have implications on decision-making about proceeding with a procedure after obtaining the INR level on the day of the procedure. The sweet spot of INR level likely falls between 2 and 2.5, a range that can be hard to predict and achieve, even with careful planning. Concomitant use of clopidogrel increased the risk of bleeding across all subgroups of INR levels; and is yet another reason to be extremely careful about performing an AF ablation when the INR is outside the most favorable range.
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Of note, clinical thromboembolic complications were rather infrequent (only 0.3% of patients). This is likely because of the careful exclusion of intracardiac clots in patients presenting with subtherapeutic INR, and the adequate use of antithrombotic therapy in the periprocedural period. Because the total number of events was very small, there was no relation between the baseline INR level and the occurrence of a thromboembolic event.
This study confirms the relation between baseline INR and heparin requirements to achieve target activated clotting time during the procedure. Patients with an INR >2 required approximately half the total intraprocedural dose of heparin compared with patients with an INR <2. As stated by the authors, this finding is useful in determining the initial bolus dose of heparin. Because this is usually given around the time of atrial septal puncture, it may avoid an excessive anticoagulation that may increase the risk of pericardial effusion.
Kim et al 1 have thus reinforced the concept that patients taking warfarin should continue the medication when undergoing AF ablation. The best balance between risk of bleeding and risk of thromboembolic events is likely to be with an INR between 2 and 2.5, but from a practical standpoint the procedure can be still performed safely as long as the INR does not exceed 3. The study remains relevant despite the introduction and increasing usage of warfarin alternatives, such as dabigatran, rivaroxaban, and apixaban, because many if not most patients are still managed with warfarin before and after AF ablation procedures.
The study raises other questions; however, What is the best management for patients with subtherapeutic INRs (<2.0) on the procedure day? Because thromboembolic events are very rare, Should these patients have less aggressive postprocedural anticoagulation than is currently practiced, to avoid bleeding problems described by the authors? Likewise, What should be done with patients whose INR is ≥3.5 on the procedure day-Should they be rescheduled to a time when
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April 2013 the INR is lower, or given fresh frozen plasma to bring the INR to the desired range? Should the preprocedural INR be individualized? For instance, in a patient with a history of a bleeding tendency, Should a lower INR with less aggressive postprocedural anticoagulation be used? Whereas in a patient who has a high CHADS-2 score or prior stroke, is a higher INR desirable? Further research is necessary to clarify whether it will be desirable or feasible for physicians to optimize and individualize periprocedural anticoagulation to pick the poison (dose) for our patients to achieve the safest outcomes.
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